Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

Inclusion Criteria: * 18 years of age and older who have biopsy-proven resectable pancreatic cancer * Participants must have a histological diagnosis of pancreatic head ductal adenocarcinoma at least ≥ 1 cm from ampula. * Participants must be able to undergo all 3 imaging modalities. * Participants' medical statuses must be considered appropriate for surgery and for general anesthesia. * Female participants and female partners of male participants undergoing optional PET-CT or CT pancreatic protocol scan cannot be pregnant or nursing, as confirmed by serum pregnancy test if the patient is a woman of child-bearing potential. * All female participants of child-bearing potential must agree to use birth control, including oral, injectable, or mechanical contraception, abstinence, or vasectomy for 30 days following pimonidazole administration. * Adequate kidney and liver function as assessed by laboratory studies. Laboratory studies must be completed within 28 days prior to pimonidazole administration; * Must be capable of providing informed consent and demonstrate a willingness to comply with all the study procedures and visits; * Must be able to undergo MRI scans without having a pacemaker or other indwelling metal, which would contraindicate the scan. * Have an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2. Exclusion Criteria: * Women who are pregnant or breastfeeding * Participants who are contraindicated for MRI or gadolinium contrast agents. * If the patient has an iodine contrast allergy, they must be able to take standard pre-medications so they can safely undergo a CT scan. * Participants with a known active cancer with a prognosis that would contraindicate a curative intent pancreatic resection. * Participants with depressed liver function, as assessed with a screening liver function test yielding serum ALT or AST greater than the IULN or total bilirubin greater than 2 mg/dL. * Presence of any other co-existing condition, which, in the judgment of the investigator, might increase the risk to the patient.